Co-formulation players with anti-VEGF, PDGF are taking 'shots' in AMD market
By Randy Osborne
Staff Writer
Staff Writer
Tuesday, May 20, 2014
Ophthotech Corp.'s potential $1 billion-plus, ex-U.S. deal with Novartis AG for Fovista, the antiplatelet-derived growth factor (PDGF) agent capable of enhancing the efficacy of anti-VEGF therapies in wet age-related macular degeneration (AMD), added juice to a growing $5 billion market one about to take the next step into co-formulation.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.